Precision Business Insights
Portfolio

 

Research Reports

Mesothelioma Treatment Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Mesothelioma Treatment Market

 

By Drug Class (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), By Application (Pleural Mesothelioma and Peritoneal Mesothelioma), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

 

Global mesothelioma treatment market was valued at US$ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024

 

Market Outline: Mesothelioma Treatment Market

Mesothelioma is a rare and aggressive form of cancer that occurs in the thin layer tissue that covers the majority of the internal organs. Mesothelioma most often affects the tissue that surrounds the lungs (pleura), which is called pleural mesothelioma. Other, rarer types of mesothelioma affect tissue in the abdomen (peritoneal mesothelioma), around the heart and around the testicles. Pleural mesothelioma is the most common type of mesothelioma. Mesothelioma primarily caused by the inhalation of asbestos fibers, can be diagnosed in older individuals who worked with asbestos products in an industrial setting as there is no cure currently exists, mesothelioma patients can usually improve their prognosis through some form of treatment available.

 

Market Dynamics: Mesothelioma Treatment Market

Out of all types of mesothelioma, malignant pleural mesothelioma segment is anticipated to grow at significant rate and accounts for 70% of all mesothelioma cases followed by malignant peritoneal mesothelioma which accounts 15-20% of all mesothelioma cases. Many companies are focusing on the collaborations in order to study the combinations of various drugs. The combination therapies are improving the survival rates which is encouraging the R&D activities. According to the Cancer Research UK, 1 in every 140 men and 1 in every 710 women are diagnosed with malignant mesothelioma. The increasing cases of malignant mesothelioma are adding fuel to the mesothelioma treatment market growth.

 

Market Scope: Mesothelioma Treatment Market

Mesothelioma treatment market is segmented based on the product type, technology, disease indication, and distribution channel

Based on the drug class the market is segmented into the following:

  • Alkylating agents
  • Antimetabolites
  • Plant alkaloids
  • Antitumor Antibiotics
  • Others

Based on the application, the market is segmented into the following:

  • Pleural Mesothelioma
  • Peritoneal Mesothelioma

Based on the route of administration, the market is segmented into the following:

  • Oral
  • Parenteral

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Geographically, global mesothelioma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Asia-Pacific dominates the mesothelioma treatment market due to the growing prevalence of mesothelioma in the region. The increasing geriatric population is also driving the growth of the mesothelioma treatment market. The poor reimbursement policies may hamper the growth of the global mesothelioma treatment market.

 

Competition Assessment: Mesothelioma Treatment Market

Some of the players in the global mesothelioma treatment market include:

  • Teva Pharmaceuticals (Israel)
  • Boehringer Ingelheim GmbH (Germany)
  • Mylan N.V. (U.S)
  • Fresenius Kabi AG (Germany)
  • Sun Pharmaceuticals Industries Ltd. (India)
  • Concordia International Corp. (U.K)
  • Kyowa Hakko Kirin Co Ltd. (Japan)
  • MolMed SpA (Italy)
  • Ono Pharmaceutical Co. Ltd. (Japan)
  • Nichi-Iko Pharmaceutical Co. (Japan)

 

Notable Market Developments: Mesothelioma Treatment Market

  • In February 2016, AstraZeneca reported top-line result of tremelimumab monotherapy trial in mesothelioma.

 

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (The USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Venezuela, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenari0
  • Teva Pharmaceuticals (Israel)
  • Boehringer Ingelheim GmbH (Germany)
  • Mylan N.V. (U.S)
  • Fresenius Kabi AG (Germany)
  • Sun Pharmaceuticals Industries Ltd. (India)
  • Concordia International Corp. (U.K)
  • Kyowa Hakko Kirin Co Ltd. (Japan)
  • MolMed SpA (Italy)
  • Ono Pharmaceutical Co. Ltd. (Japan)
  • Nichi-Iko Pharmaceutical Co. (Japan)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements